Urovant Sciences, Inc

75 articles with Urovant Sciences, Inc

• 

  M&A for 2019 was Big; Will 2020 Be Even Bigger?

  1/13/2020

  Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.

• Urovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

  1/8/2020

  Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 4:30 p.m. Pacific / 7:30 p.m. Eastern on Wednesday, January 15, 2020, at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

• Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder

  12/30/2019

  Urovant Sciences announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval of once-daily 75mg vibegron for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

• Urovant Sciences Majority Shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Complete Transaction for Strategic Alliance

  12/30/2019

  Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that its majority shareholder, Roivant Sciences Ltd. (“Roivant”), and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical company, have completed their transaction that creates a significant, multinational Sumitomo Dainippon Pharma-Roivant Alliance

• Urovant Sciences Enters into $300 Million Term Loan Agreement with Sumitomo Dainippon Pharma

  12/30/2019

  Urovant expects to borrow $87.5M under this facility of which approximately $48 million will be used to repay Urovant’s outstanding Hercules Capital loans in full.

• Urovant Sciences Initiates Patient Enrollment in Phase 2a Study of URO-902

  12/23/2019

  Urovant Sciences (Nasdaq: UROV), announced today that the first patient has been enrolled in a Phase 2a study evaluating the efficacy and safety of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) suffering with urge urinary incontinence (UUI).

• Urovant Sciences Reports 2019 Second Fiscal Quarter Financial Results

  11/5/2019

  Urovant Sciences, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, reported financial results for the 2019 second fiscal quarter ended September 30, 2019.

• Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections from Sumitomo Dainippon Pharma Upon Close of Sumitomo Dainippon Pharma’s Transaction with Roivant Sciences

  10/31/2019

  Sumitomo Dainippon Pharma has committed to provide an initial $200 million, low-interest, interest-only, five-year term loan facility, with no repayments due until the end of the term

• Urovant Sciences to Report 2019 Second Fiscal Quarter Financial Results

  10/29/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 second fiscal quarter financial results after the close of U.S. financial markets on Tuesday, November 5, 2019.

• Urovant Sciences Initiates Part 2 of Phase 3 COURAGE Study of Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia

  10/21/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced that it will be initiating part 2 of the COURAGE study, an international phase 3 trial to evaluate the safety and efficacy of vibegron for the treatment of symptoms of overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH).

• Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder

  9/24/2019

  Vibegron further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period

• Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance

  9/6/2019

  Urovant Sciences (Nasdaq: UROV) today announced that its parent company, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading global Japanese pharmaceutical company, have entered into a non-binding memorandum of understanding for the creation of a significant multi-national Sumitomo Dainippon-Roivant Alliance (“Alliance”) that will include Roivant’s ownership interests in Urovant Sciences and four additional biopharmaceutical “Vant” companies.

• Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results

  8/13/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal quarter ended June 30, 2019.

• Urovant Sciences to Report 2019 First Fiscal Quarter Financial Results

  8/6/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 first fiscal quarter financial results after the close of U.S. financial markets on Tuesday, August 13, 2019.

• Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019

  6/13/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2019.

• Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019

  6/6/2019

  Will report financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2019 after the close of U.S. financial markets on Thursday, June 13, 2019.

• Urovant Sciences to Present at Annual Roivant Pipeline Day

  6/3/2019

  Urovant Sciences announced Chief Executive Officer Keith A. Katkin will present at the annual Roivant Pipeline Day on June 6, 2019 at 1:50 p.m. ET.

• Urovant Sciences to Present at the Jefferies 2019 Healthcare Conference

  5/30/2019

  Urovant Sciences, announced Chief Executive Officer Keith A. Katkin is scheduled to present a corporate overview at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 11:30 a.m. ET.

• 

  Clinical Catch-up from Last Week: May 5-10

  5/13/2019

  Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.

• Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting

  5/6/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced Dr. David Staskin presented positive, Phase 3 pivotal data demonstrating safety and efficacy of vibegron during a plenary session at the 2019 American Urological Association Annual Meeting (AUA) in Chicago yesterday afternoon.